Microbot reported positive data on its single-use endovascular robot. Elsewhere, GE Healthcare named a new business leader, ...

With the latest round of tariffs from the Trump administration in early April 2025, investors and business owners alike are ...

The race to put humanoid robots into mass production has intensified over the past week, as companies in both the US and China made a string of announcements that convinced analysts the technology ...

A six-year-old boy has been able to enjoy a virtual experience of a school trip, thanks to a small robot. Rufus, who has Down's syndrome, was unable to join classmates on a museum visit due to ...

I'm PCMag's managing editor for consumer electronics, overseeing an experienced team of analysts covering smart home, home entertainment, wearables, fitness and health tech, and various other ...

GameSpot may get a commission from retail offers. At some point during your Atomfall playthrough, you'll come across a massive, hulking robot. These robots are all over Atomfall and can come in a ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE ... U.S. is grappling with a significant labor shortage, and robots, capable of handling tedious, hazardous, and ...

Figure AI has developed a new humanoid robotic natural walking capability for its humanoid robots, leveraging reinforcement learning (RL) and simulation-based training. This approach enables the ...

"We see that the Chinese government's sustained emphasis is on transforming the country toward high-quality growth driven by new quality productive forces," Marc Horn, president of Merck China ...

You can find his previous stuff at Gizmodo and Paste if you look hard enough. Scientists Break the Humanoid Robot Speed Record Robots in the Trenches Are Reshaping Warfare.

Opinions expressed are those of the author. The world of automation is evolving rapidly, and collaborative robots (cobots) are leading the charge. Unlike traditional industrial robots that operate ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.